EXPLORING UNCHARTED BIOLOGICAL FRONTIERS
RyboDyn focuses on the dark transcriptome and proteome—regions long considered biologically silent. With RyboCypher™, our proprietary sequencing and AI-driven target discovery platform, we decode these hidden layers and transform cryptic biological signals into breakthrough immunotherapies.
DARK TRANSCRIPTOME /// DARK GENOME /// DARK PROTEOME
///
DARK TRANSCRIPTOME /// DARK GENOME /// DARK PROTEOME ///
For decades, scientists believed that only about 2% of the human genome encoded proteins. The rest—non-coding regions—was labeled “junk DNA.” But research has since shown that the dark genome holds far more than we imagined.
At RyboDyn, we explore these non-coding regions, including what’s now known as the dark transcriptome: RNA molecules transcribed from genomic regions previously dismissed as non-functional. These overlooked RNAs often encode cryptic proteins—components of the dark proteome—that standard methods fail to detect.
These hidden molecules are abundant and functional in cells—they’re not noise. They’re overlooked signals. And they hold vital clues to understanding disease.
RYBOCYPHER™
THE ENGINE OF DISCOVERY
RyboCypher™ pairs high-resolution RNA sequencing with AI models built on our proprietary transcriptomic and proteomic datasets to predict proteins arising from what were previously considered non-coding RNAs. This advanced pattern-recognition framework exposes the dark proteome with unprecedented clarity—revealing disease-specific antigens and accelerating the discovery of actionable Dark Targets™ for transformative immunotherapies.
RyboCypher™ enables us to:
Decipher uncharacterized RNA with high-resolution
Detect proteins overlooked by traditional sequencing
Reveal cryptic, disease-specific peptides
Identify Dark Targets™ at unparalleled scale
Early impact: Initial datasets uncovered 8,000+ previously unseen peptides, more than 1,000 unique to cancer cells—opening a new frontier for immunotherapy development.
“We knew this class of RNA molecules existed in cells before we developed RyboCypher to observe them at high resolution. What we didn’t realize was how much protein is being produced from them.”
—Dr. Corey Dambacher, Co-Founder, President & Chief Technical Officer of RyboDyn
DARK TARGETS™
FINDING SIGNALS WHERE OTHERS SEE SILENCE
Dark Targets™ are previously undiscovered, druggable targets that are disease-specific, representing unique chemical handles on the surface of cells. These molecules are undetectable using conventional tools, and were therefore missed in previous studies. By isolating and decoding these targets, we can design immunotherapies that zero in on what makes diseased cells unique.
FROM DISCOVERY TO THERAPEUTICS
BRIDGING SCIENCE AND CLINICAL INNOVATION
At RyboDyn, discovery is just the beginning. Once Dark Targets™ are identified and validated, we apply a rigorous development process to advance them into a robust pipeline of antibody-based drug candidates.
Our therapeutics are engineered for:
High specificity
Low off-target risk
Scalability for broad clinical use
This approach enables the development of off-the-shelf immunotherapies to reach broad patient populations.
“We’re pioneering first-in-class therapies for those who need them the most—building new paths for neglected patients.”
— Imad Ajjawi, PhD, MBA, Co-founder & CEO of RyboDyn
ACCELERATING TRANSLATION THROUGH STRATEGIC PARTNERSHIPS
Our collaboration with Moffitt Cancer Center—a global leader in oncology—has played a critical role in validating our approach. Together, we are defining Dark Targets™ across a diverse range of tumor types using Moffitt’s uniquely annotated tumor repository.
This collaboration confirms that select Dark Targets™ are:
Conserved across patient samples
Absent in healthy tissue
Therapeutically actionable
These findings give us high confidence in the clinical relevance of our targets and strengthen the foundation of our immunotherapy pipeline.
“Moffitt’s tumor bank is a critical resource in validating novel targets across a diverse set of cancer patients. The ability to correlate molecular signals with deep clinical metadata significantly accelerates both discovery and translational development.”
— Dr. Alex Jaeger, Assistant member of the Molecular Oncology Department at Moffitt Cancer Center.
CONTINUOUS INNOVATION
REDEFINING POSSIBILITIES IN IMMUNOTHERAPY
Scientific progress is not a destination—it’s a discipline. Our team continuously refines our methods, platforms, and hypotheses to stay ahead of the curve and push the boundaries of biomedical discovery.
By making the invisible visible, we’re setting a new standard in target discovery and helping define the next era of immunotherapy.